An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report.
Humans
Female
Aged, 80 and over
Adrenal Insufficiency
/ diagnosis
Adrenal Gland Neoplasms
/ diagnosis
17-alpha-Hydroxyprogesterone
/ blood
Adrenal Hyperplasia, Congenital
Treatment Outcome
Aldosterone
/ blood
Glucocorticoids
/ therapeutic use
Mineralocorticoids
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Addison disease
Adrenal incidentaloma
Case report
Corticosteroids
Lymphoma
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
29 May 2023
29 May 2023
Historique:
received:
28
09
2022
accepted:
14
05
2023
medline:
30
5
2023
pubmed:
29
5
2023
entrez:
28
5
2023
Statut:
epublish
Résumé
We present an intriguing case of primary adrenal lymphoma, with associated primary adrenal insufficiency (PAI), in a patient presenting a transitory partial 21-hydroxylase deficiency during the active phase of the adrenal disease. An 85-years old woman was referred because of worsening asthenia, lumbar pain, generalized myalgia and arthralgia. During investigations a computed tomography (CT) scan evidenced two large bilateral adrenal masses, highly suspicious for primary adrenal tumor. The hormonal assessment revealed very low levels of morning plasma cortisol and 24-h urinary cortisol, elevated ACTH levels with low plasma concentration of aldosterone, pointing to the diagnosis of PAI. After diagnosis of PAI our patient started glucocorticoid and mineralcorticoid replacement therapy with clinical benefit. In order to further characterize the adrenal lesions, adrenal biopsy, was performed. The histology revealed a high grade non-Hodgkin lymphoma with an immunophenotype consistent with intermediate aspects between diffuse large B-cell and Burkitt lymphoma, with a high proliferation index (KI-67 > 90%). The patient received chemotherapy with epirubicin, vincristine, cyclophosphamide, and rituximab, associated with methylprednisolone that resulted in a complete clinical and radiological remission within one year. After 2 years from the diagnosis and a total of 6 cycles of rituximab, the patient was in good clinical condition and was taking only the replacement therapy for PAI. The patient initially presented also a slight increase of 17-hydroxyprogesterone (17-OHP) for age that normalize after resolution of lymphoproliferative disease. In the presence of bilateral adrenal disease and/or in the presence of signs and symptoms of PAI clinicians must exclude the presence of PAL. The evidence of elevated ACTH-stimulated 17-OHP levels also in patients with other adrenal masses, together with the detection of elevated basal 17-OHP levels in our patient make it more plausible, in our view, an effect of the lesion on the "healthy" adrenal tissue residue than a direct secretory activity by the adrenal tumor.
Sections du résumé
BACKGROUND
BACKGROUND
We present an intriguing case of primary adrenal lymphoma, with associated primary adrenal insufficiency (PAI), in a patient presenting a transitory partial 21-hydroxylase deficiency during the active phase of the adrenal disease.
CASE PRESENTATION
METHODS
An 85-years old woman was referred because of worsening asthenia, lumbar pain, generalized myalgia and arthralgia. During investigations a computed tomography (CT) scan evidenced two large bilateral adrenal masses, highly suspicious for primary adrenal tumor. The hormonal assessment revealed very low levels of morning plasma cortisol and 24-h urinary cortisol, elevated ACTH levels with low plasma concentration of aldosterone, pointing to the diagnosis of PAI. After diagnosis of PAI our patient started glucocorticoid and mineralcorticoid replacement therapy with clinical benefit. In order to further characterize the adrenal lesions, adrenal biopsy, was performed. The histology revealed a high grade non-Hodgkin lymphoma with an immunophenotype consistent with intermediate aspects between diffuse large B-cell and Burkitt lymphoma, with a high proliferation index (KI-67 > 90%). The patient received chemotherapy with epirubicin, vincristine, cyclophosphamide, and rituximab, associated with methylprednisolone that resulted in a complete clinical and radiological remission within one year. After 2 years from the diagnosis and a total of 6 cycles of rituximab, the patient was in good clinical condition and was taking only the replacement therapy for PAI. The patient initially presented also a slight increase of 17-hydroxyprogesterone (17-OHP) for age that normalize after resolution of lymphoproliferative disease.
CONCLUSIONS
CONCLUSIONS
In the presence of bilateral adrenal disease and/or in the presence of signs and symptoms of PAI clinicians must exclude the presence of PAL. The evidence of elevated ACTH-stimulated 17-OHP levels also in patients with other adrenal masses, together with the detection of elevated basal 17-OHP levels in our patient make it more plausible, in our view, an effect of the lesion on the "healthy" adrenal tissue residue than a direct secretory activity by the adrenal tumor.
Identifiants
pubmed: 37246209
doi: 10.1186/s12902-023-01374-7
pii: 10.1186/s12902-023-01374-7
pmc: PMC10226195
doi:
Substances chimiques
17-alpha-Hydroxyprogesterone
68-96-2
Aldosterone
4964P6T9RB
Glucocorticoids
0
Mineralocorticoids
0
Antineoplastic Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Informations de copyright
© 2023. The Author(s).
Références
J Endocrinol Invest. 1996 Dec;19(11):745-52
pubmed: 9061508
J Clin Endocrinol Metab. 1993 Sep;77(3):677-82
pubmed: 8370688
Front Endocrinol (Lausanne). 2021 Apr 02;12:636658
pubmed: 33868171
Endocr J. 1997 Oct;44(5):647-53
pubmed: 9466319
Ann Hematol. 2013 Dec;92(12):1583-93
pubmed: 23771429
Clin Endocrinol (Oxf). 1994 Oct;41(4):445-51
pubmed: 7955456
Cancer. 1993 Jun 15;71(12):4030-3
pubmed: 8508368
Ann Hematol. 1999 Mar;78(3):151-4
pubmed: 10211758
Eur J Case Rep Intern Med. 2022 Jan 13;9(1):003116
pubmed: 35169576
J Clin Endocrinol Metab. 2013 Aug;98(8):3131-8
pubmed: 23714679
Endocr Pract. 2009 Jul-Aug;15(5):450-3
pubmed: 19632968
Clin Lymphoma. 2003 Dec;4(3):154-60
pubmed: 14715097
Endocrine. 2015 Sep;50(1):32-50
pubmed: 26082286
Am J Hematol. 1998 Jun;58(2):130-6
pubmed: 9625581
Leuk Lymphoma. 1997 Jan;24(3-4):363-7
pubmed: 9156667
QJM. 2017 Feb 01;110(2):103-109
pubmed: 27795295
J Med Case Rep. 2017 Apr 15;11(1):108
pubmed: 28410600
Eur J Endocrinol. 2011 Jun;164(6):851-70
pubmed: 21471169
J Endocrinol Invest. 1992 Dec;15(11):789-96
pubmed: 1337905
Ann Clin Biochem. 2014 Jul;51(Pt 4):424-40
pubmed: 24711560
Front Endocrinol (Lausanne). 2020 Sep 24;11:595
pubmed: 33071959
Eur J Endocrinol. 1995 Apr;132(4):422-8
pubmed: 7711879
BMJ Case Rep. 2016 Oct 26;2016:
pubmed: 27797844
N Engl J Med. 2021 Jan 14;384(2):165
pubmed: 33497550
Br Foreign Med Chir Rev. 1856 Oct;18(36):404-413
pubmed: 30164929
BMJ Case Rep. 2016 Mar 18;2016:
pubmed: 26994055
BMJ Case Rep. 2013 Jan 11;2013:
pubmed: 23314877
J Clin Endocrinol Metab. 1996 Feb;81(2):740-4
pubmed: 8636297
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044
J Endocrinol Invest. 2000 May;23(5):287-94
pubmed: 10882146
Endocr J. 2008 Aug;55(4):625-38
pubmed: 18490838
Cancer. 1972 Jan;29(1):252-60
pubmed: 5007387